← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2010Last known activity
Dec 31, 2024
Timeline
1990s
- Jan 1, 1995
Banc de Sang i Teixits— Founded
Drugs by trial phase (20 distinct, 20 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (14 own, 0 via acquisition)
- autologous t cells
- aldesleukin
- fibrinogen (human)
- red blood cells
- cyclophosphamide
- allogeneic cord blood
- autologous iliac crest
- autologous bone marrow derived mesenchymal cells
- autologous mesenchymal stem cells
- wharton's jelly mesenchymal stem cells
- fludarabine
- tumour infiltrating lymphocytes
- blood plasma
- COVID-19 convalescent plasma
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Communicable Diseases
- Femoral Neck Fractures
- Femur Head Necrosis
- Fractures, Bone
- Fractures, Ununited
- Hemorrhage
- Infections
- Joint Diseases
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Trauma
- Necrosis
- Osteonecrosis
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sclerosis
- Spinal Cord Injuries
- Spondylolisthesis
- Syndrome
- Viremia
- Wounds and Injuries
Recent trials (21)
- NCT06630611CollaboratorPhase 2Dec 31, 2024
- NCT05612919CollaboratorN/AJan 31, 2023
- NCT05445674CollaboratorPhase 2Sep 22, 2022
- NCT05385705CollaboratorPhase 1May 11, 2022
- NCT05054803Lead sponsorPhase 1/Phase 2Oct 31, 2021
- NCT05141474CollaboratorEarly Phase 1Oct 28, 2021
- NCT04621123CollaboratorPhase 2Oct 30, 2020
- NCT04390139Lead sponsorPhase 1/Phase 2May 13, 2020
- NCT04018261Lead sponsorPhase 1/Phase 2Jul 4, 2019
- NCT03780894Lead sponsorPhase 1/Phase 2Nov 21, 2018
- NCT03084861Lead sponsorPhase 1/Phase 2Feb 24, 2017
- NCT03084861Overall official - principal investigatorPhase 1/Phase 2Feb 24, 2017
- NCT03003364Lead sponsorPhase 1/Phase 2Dec 27, 2016
- NCT02630836Lead sponsorPhase 1/Phase 2Dec 1, 2015
- NCT02495766Lead sponsorPhase 1/Phase 2May 1, 2015
Details
- Founded
- Barcelona, ES Jan 1, 1995
- Last known activity
- Dec 31, 2024